RCKT Stock Price, Rocket Pharmaceuticals Quote, Chart

Market Summary

USD23.40+0.31

Market Closed

1.34%

RCKT Alerts

2 major insider sales recently.

RCKT Stock Price

View Fullscreen

RCKT RSI Chart

RCKT Valuation

Market Cap

2.1B

Price/Earnings (Trailing)

-8.41

Price/Sales (Trailing)

327.07

Price/Free Cashflow

-10

RCKT Price/Sales (Trailing)

RCKT Profitability

Return on Equity

-56.47%

Return on Assets

-49.92%

Free Cashflow Yield

-10%

RCKT Fundamentals

RCKT Revenue

Revenue (TTM)

6.4M

Rev. Growth (Yr)

58.75%

Rev. Growth (Qtr)

272.11%

RCKT Earnings

Earnings (TTM)

-249.3M

Earnings Growth (Yr)

-6.38%

Earnings Growth (Qtr)

-4.01%

Breaking Down RCKT Revenue

Last 7 days

-0.3%

Last 30 days

-4.4%

Last 90 days

-20.2%

Trailing 12 Months

15.8%

How does RCKT drawdown profile look like?

RCKT Financial Health

Current Ratio

10.47

RCKT Investor Care

Shares Dilution (1Y)

12.83%

Diluted EPS (TTM)

-2.85

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	6.4M	0	0	0
2023	5.2M	5.4M	5.7M	5.3M
2022	2.8M	2.9M	3.5M	3.9M
2021	2.1M	2.2M	2.5M	3.1M
2020	3.8M	3.2M	2.8M	2.2M
2019	2.0M	2.5M	3.1M	3.4M
2018	0	0	0	1.7M
2017	0	0	0	0
2016	0	0	0	0

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Rocket Pharmaceuticals Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 22, 2024	militello john	sold	-19,050	22.87	-833	see remarks
Apr 15, 2024	southwell david p	acquired	128,627	4.342	29,624	-
Apr 15, 2024	southwell david p	sold	-240,520	24.052	-10,000	-
Apr 12, 2024	southwell david p	acquired	303,940	4.342	70,000	-
Apr 12, 2024	southwell david p	sold	-1,705,260	24.3609	-70,000	-
Apr 08, 2024	white mark andrew	sold	-308,763	24.638	-12,532	see remarks
Apr 01, 2024	ondrey aaron	acquired	-	-	46,781	chief financial officer
Mar 21, 2024	makker gotham	sold	-7,790,940	28.4341	-274,000	-
Mar 21, 2024	militello john	sold	-69,979	28.104	-2,490	see remarks
Feb 29, 2024	militello john	acquired	125,500	12.55	10,000	see remarks

Which funds bought or sold RCKT recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 13, 2024	CANADA LIFE ASSURANCE Co	unchanged	-	-18,000	169,000	-%
May 13, 2024	NOMURA ASSET MANAGEMENT CO LTD	sold off	-	-	-	-%
May 13, 2024	HARBOR CAPITAL ADVISORS, INC.	added	49.8	564,981	2,194,000	0.29%
May 13, 2024	RENAISSANCE TECHNOLOGIES LLC	sold off	-100	-1,878,000	-	-%
May 13, 2024	AMERICAN INTERNATIONAL GROUP, INC.	reduced	-0.85	-101,653	832,931	-%
May 13, 2024	GMT CAPITAL CORP	reduced	-24.96	-2,989,600	6,196,200	0.24%
May 13, 2024	Ameritas Investment Partners, Inc.	unchanged	-	-19,677	174,948	0.01%
May 10, 2024	a16z Perennial Management, L.P.	unchanged	-	-34,345	305,365	0.03%
May 10, 2024	JPMORGAN CHASE & CO	reduced	-8.79	-4,040,550	18,387,200	-%
May 10, 2024	PRINCIPAL SECURITIES, INC.	sold off	-100	-270	-	-%

Are Funds Buying or Selling RCKT?

Are funds buying RCKT calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own RCKT

No. of Funds

RCKT Alerts

2 major insider sales recently.

Unveiling Rocket Pharmaceuticals Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Apr 05, 2024	wellington management group llp	10.12%	9,156,099	SC 13G/A
Feb 13, 2024	vanguard group inc	6.04%	5,447,565	SC 13G/A
Feb 08, 2024	wellington management group llp	9.09%	8,197,546	SC 13G
Jan 29, 2024	blackrock inc.	6.6%	5,930,178	SC 13G/A
Jan 22, 2024	state street corp	3.58%	3,231,411	SC 13G/A
Sep 19, 2023	rtw investments, lp	20.21%	18,188,457	SC 13D/A
Apr 05, 2023	rtw investments, lp	22.9%	18,188,457	SC 13D/A
Feb 09, 2023	vanguard group inc	5.32%	4,186,542	SC 13G/A
Feb 06, 2023	wellington management group llp	4.45%	3,507,017	SC 13G/A
Jan 31, 2023	state street corp	5.05%	3,978,985	SC 13G

Recent SEC filings of Rocket Pharmaceuticals Inc

View All Filings

Date Filed	Form Type	Document
May 07, 2024	10-Q	Quarterly Report
May 06, 2024	8-K	Current Report
Apr 29, 2024	ARS	ARS
Apr 29, 2024	DEF 14A	DEF 14A
Apr 29, 2024	DEFA14A	DEFA14A
Apr 24, 2024	4	Insider Trading
Apr 22, 2024	144	Notice of Insider Sale Intent
Apr 17, 2024	PRE 14A	PRE 14A
Apr 16, 2024	4	Insider Trading
Apr 15, 2024	144	Notice of Insider Sale Intent

Peers (Alternatives to Rocket Pharmaceuticals Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	48.2B	6.8B	19.54%	-2.80%	-8.07	7.03	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	19.0B	2.0B	0.98%	-26.98%	-57.12	9.47	75.20%	68.82%
BMRN	15.3B	2.5B	-12.72%	-14.31%	74.39	6.18	13.74%	186.89%
INCY	12.9B	3.8B	6.98%	-11.75%	17.35	3.43	8.58%	129.81%
MID-CAP
BBIO	5.3B	107.9M	6.22%	110.41%	-9.76	48.09	54.84%	-28.31%
APLS	5.2B	524.1M	-16.95%	-51.10%	-12.51	9.96	394.93%	39.61%
AXSM	3.6B	251.0M	9.36%	-4.29%	-12.12	14.31	73.58%	-86.73%
ARWR	2.7B	240.7M	-10.69%	-43.90%	-5.82	12.77	-1.03%	-213.43%
ACAD	2.5B	813.8M	-11.38%	-29.25%	-1.5K	3.08	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	6.64%	20.67%	29.44	4.66	60.38%	-34.49%
NVAX	1.8B	996.6M	206.31%	55.15%	-4.62	1.85	-26.66%	65.49%
CRBP	458.7M	881.7K	5.07%	336.18%	-13.59	481.06	-77.61%	33.36%
INO	294.6M	4.9M	3.08%	29.79%	-2.36	60.54	-54.97%	48.23%
IBIO	15.6M	2.1M	-10.40%	79.21%	-0.67	7.61	-13.45%	69.54%

Rocket Pharmaceuticals Inc News

Latest updates

Rocket Pharmaceuticals Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	272.1%	3,029	814	1,720	846	1,908	1,245	1,353	669	623	850	806	501	911	237	518	429	967	863	979	1,000	601
Operating Expenses	6.5%	67,375	63,279	65,429	68,757	62,194	69,082	58,488	54,210	42,564	44,333	49,646	34,048	39,222	59,237	27,387	23,559	24,120	19,649	19,165	18,392	18,945
S&GA Expenses	-100.0%	-	21,535	18,585	17,374	15,823	19,045	15,105	12,854	11,770	11,316	10,025	9,518	10,913	9,145	5,730	6,828	7,163	5,697	4,336	4,403	3,808
R&D Expenses	8.3%	45,227	41,744	46,844	51,383	46,371	50,037	43,383	41,356	30,794	33,017	39,621	24,530	28,309	50,093	21,657	16,731	16,957	13,952	14,829	13,989	15,137
Interest Expenses	0.2%	471	470	469	468	468	468	465	465	464	463	534	251	1,729	1,641	1,967	1,786	1,573	1,344	1,466	1,544	1,604
Income Taxes	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	26.00	-	-	-
Net Income	-4.0%	-62,054	-59,660	-61,899	-65,701	-58,335	-66,723	-57,756	-54,402	-42,982	-44,247	-50,118	-34,525	-40,179	-60,916	-29,080	-25,040	-24,664	-19,855	-19,284	-18,680	-19,451
Net Income Margin	16.2%	-38.90*	-46.44*	-44.18*	-46.44*	-45.84*	-57.04*	-57.05*	-65.04*	-61.82*	-55.11*	-75.67*	-76.02*	-	-	-	-	-	-	-	-	-
Free Cashflow	-73.3%	-58,891	-33,986	-61,803	-54,988	-60,575	-59,024	-44,362	-41,936	-41,178	-32,906	-31,294	-39,972	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-11.8%	499	566	599	462	515	552	417	432	460	497	530	535	576	591	335	353	373	372	300	309	242
Current Assets	-8.7%	345	378	447	312	338	364	311	326	354	392	425	430	472	487	233	255	280	308	246	264	200
Cash Equivalents	-34.5%	37.00	56.00	226	45.00	65.00	141	198	189	132	234	247	266	254	299	84.00	165	192	187	91.00	66.00	126
Net PPE	0.4%	39.00	39.00	37.00	33.00	31.00	29.00	26.00	25.00	24.00	22.00	22.00	21.00	20.00	19.00	16.00	14.00	11.00	30.00	19.00	10.00	7.00
Goodwill	0.1%	39.00	39.00	39.00	39.00	39.00	39.00	31.00	31.00	31.00	31.00	31.00	31.00	31.00	31.00	31.00	31.00	31.00	31.00	31.00	31.00	31.00
Liabilities	-21.5%	58.00	74.00	58.00	59.00	56.00	62.00	50.00	44.00	43.00	42.00	45.00	46.00	96.00	87.00	94.00	87.00	87.00	65.00	68.00	60.00	65.00
Current Liabilities	-32.1%	33.00	49.00	33.00	34.00	31.00	39.00	30.00	24.00	23.00	22.00	24.00	25.00	40.00	33.00	32.00	21.00	21.00	18.00	22.00	15.00	21.00
Shareholder's Equity	-10.4%	442	493	541	403	459	490	367	388	418	455	486	489	480	504	242	267	286	307	232	249	177
Retained Earnings	-6.3%	-1,020	-959	-899	-837	-772	-713	-647	-589	-534	-491	-447	-397	-363	-322	-261	-232	-207	-183	-163	-144	-125
Additional Paid-In Capital	0.8%	1,462	1,451	1,440	1,241	1,230	1,203	1,014	977	952	946	933	886	842	826	503	499	494	490	395	392	302
Shares Outstanding	0.4%	91.00	90.00	90.00	81.00	80.00	79.00	66.00	65.00	65.00	63.00	63.00	62.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	1,200	-	-	-	644	-	-	-	1,900	-	-	-	735	-	-	-	463	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-93.8%	-56,856	-29,339	-57,148	-50,869	-57,560	-56,021	-43,859	-39,039	-39,223	-30,941	-27,413	-38,526	-24,283	-13,109	-17,253	-22,033	-22,245	-19,733	-10,849	-18,104	-15,977
Share Based Compensation	3.2%	10,252	9,930	10,316	10,245	8,915	9,693	7,677	7,369	6,270	7,037	6,989	7,311	7,900	6,070	4,047	4,489	3,961	3,359	2,693	4,139	3,180
Cashflow From Investing	124.9%	35,034	-140,805	48,254	31,206	-36,721	-108,585	23,465	78,789	-62,995	16,864	-18,189	49,352	-29,174	-54,462	-64,193	-5,435	27,499	23,514	35,180	-126,880	29,175
Cashflow From Financing	202.8%	1,184	391	189,485	182	18,343	108,440	29,526	17,246	76.00	1,136	26,638	1,115	8,792	282,443	512	151	-117	92,407	31.00	85,353	-
Buy Backs	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	72.00	-727	-	-	727

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

RCKT Income Statement

2024-03-31

Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Consolidated Statements of Operations [Abstract]
Revenue	$ 0	$ 0
Operating expenses:
Research and development	45,227	46,371
General and administrative	22,148	15,823
Total operating expenses	67,375	62,194
Loss from operations	(67,375)	(62,194)
Interest expense	(471)	(468)
Interest and other income, net	3,029	1,908
Accretion of discount on investments, net	2,763	2,419
Net loss	$ (62,054)	$ (58,335)
Net loss per share - basic (in dollars per share)	$ (0.66)	$ (0.73)
Net loss per share - diluted (in dollars per share)	$ (0.66)	$ (0.73)
Weighted-average common shares outstanding - basic (in shares)	93,549,884	79,453,519
Weighted-average common shares outstanding - diluted (in shares)	93,549,884	79,453,519

RCKT Balance Sheet

2024-03-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 35,276	$ 55,904
Investments	295,037	317,271
Prepaid expenses and other current assets	14,846	5,047
Total current assets	345,159	378,222
Property and equipment, net	39,337	39,172
Goodwill	39,154	39,154
Intangible assets	25,150	25,150
Restricted cash	1,362	1,372
Deposits	533	533
Investments	0	34,320
Operating lease right-of-use assets, net	4,768	3,901
Finance lease right-of-use asset, net	43,979	44,517
Total assets	499,442	566,341
Current liabilities:
Accounts payable and accrued expenses	30,085	45,789
Operating lease liabilities, current	1,064	925
Finance lease liability, current	1,808	1,791
Total current liabilities	32,957	48,505
Operating lease liabilities, non-current	3,714	2,973
Finance lease liability, non-current	19,363	19,353
Other liabilities	1,906	2,936
Total liabilities	57,940	73,767
Commitments and contingencies (Note 13)
Stockholders' equity:
Common stock, $0.01 par value, 120,000,000 shares authorized; 90,646,590 and 90,282,267 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively	906	903
Additional paid-in capital	1,462,155	1,450,722
Accumulated other comprehensive income (loss)	(135)	319
Accumulated deficit	(1,021,424)	(959,370)
Total stockholders' equity	441,502	492,574
Total liabilities and stockholders' equity	499,442	566,341
Series A Convertible Preferred Shares
Stockholders' equity:
Preferred stock
Series B Convertible Preferred Shares
Stockholders' equity:
Preferred stock

About Rocket Pharmaceuticals Inc

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure. It has license agreements with Fred Hutchinson Cancer Research Center; Centro de Investigaciones EnergÃƒÂ©ticas, Medioambientales y TecnolÃƒÂ³gicas, Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. The company is headquartered in Cranbury, New Jersey.

CEO	Dr. Gaurav D. Shah M.D.
WEBSITE	https://rocketpharma.com
INDUSTRY	Biotechnology
EMPLOYEES	240

Rocket Pharmaceuticals Inc Frequently Asked Questions

What is the ticker symbol for Rocket Pharmaceuticals Inc? What does RCKT stand for in stocks?

RCKT is the stock ticker symbol of Rocket Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Rocket Pharmaceuticals Inc (RCKT)?

As of Mon May 13 2024, market cap of Rocket Pharmaceuticals Inc is 2.1 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of RCKT stock?

You can check RCKT's fair value in chart for subscribers.

What is the fair value of RCKT stock?

You can check RCKT's fair value in chart for subscribers. The fair value of Rocket Pharmaceuticals Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Rocket Pharmaceuticals Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for RCKT so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Rocket Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether RCKT is over valued or under valued. Whether Rocket Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Rocket Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for RCKT.

What is Rocket Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Mon May 13 2024, RCKT's PE ratio (Price to Earnings) is -8.41 and Price to Sales (PS) ratio is 327.07. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. RCKT PE ratio will change depending on the future growth rate expectations of investors.